Donna H. Deacon

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

Gulsun Erdag, Jochen T. Schaefer, Mark E. Smolkin et al. · Cancer Research · 2012 · 614 citations · Full text

Medicine, Oncology, Pathology +17

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2003 · 321 citations

Medicine, Immunology, Oncology +17

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Craig L. Slingluff, Galina V. Yamshchikov, Patrice Y. Neese et al. · PubMed · 2001 · 229 citations

Medicine, Immunology, Oncology +17

Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

Craig L. Slingluff, Gina R. Petroni, Galina V. Yamshchikov et al. · Journal of Clinical Oncology · 2004 · 146 citations · Full text

Life Sciences, Immunology, Oncology +17

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

Joseph M. Obeid, Gulsun Erdag, Mark E. Smolkin et al. · OncoImmunology · 2016 · 131 citations · Full text

Life Sciences, Immunology, Oncology +17